RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.

RUNX1 (AML1) encodes the core binding factor alpha subunit of a heterodimeric transcription factor complex which plays critical roles in normal hematopoiesis. Translocations or down-regulation of RUNX1 have been linked to favorable clinical outcomes in acute leukemias, suggesting that RUNX1 may also play critical roles in chemotherapy responses in acute leukemias; however, the molecular mechanisms remain unclear. The median level of RUNX1b transcripts in Down syndrome (DS) children with acute megakaryocytic leukemia (AMkL) were 4.4-fold (P < .001) lower than that in non-DS AMkL cases. Short hairpin RNA knockdown of RUNX1 in a non-DS AMkL cell line, Meg-01, resulted in significantly increased sensitivity to cytosine arabinoside, accompanied by significantly decreased expression of PIK3CD, which encodes the delta catalytic subunit of the survival kinase, phosphoinositide 3 (PI3)-kinase. Transcriptional regulation of PIK3CD by RUNX1 was further confirmed by chromatin immunoprecipitation and promoter reporter gene assays. Further, a PI3-kinase inhibitor, LY294002, and cytosine arabinoside synergized in antileukemia effects on Meg-01 and primary pediatric AMkL cells. Our results suggest that RUNX1 may play a critical role in chemotherapy response in AMkL by regulating the PI3-kinase/Akt pathway. Thus, the treatment of AMkL may be improved by integrating PI3-kinase or Akt inhibitors into the chemotherapy of this disease.

[1]  A. Baruchel,et al.  Activating mutations in human acute megakaryoblastic leukemia. , 2008, Blood.

[2]  J. Fontana,et al.  Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group , 2008, Oncogene.

[3]  C. Pui,et al.  Acute lymphoblastic leukaemia , 2008, The Lancet.

[4]  A. Dombkowski,et al.  The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy , 2008, Leukemia.

[5]  J. Hitzler.  Acute megakaryoblastic leukemia in Down syndrome , 2007, Pediatric blood & cancer.

[6]  Danielle Boller,et al.  Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. , 2007, Critical reviews in oncology/hematology.

[7]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[8]  C. Bloomfield,et al.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A M Martelli,et al.  Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia , 2006, Leukemia.

[10]  M. Loh,et al.  Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. , 2006, Blood.

[11]  F. Ferrara,et al.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. , 2006, Blood.

[12]  Hongyue Dai,et al.  Rosetta error model for gene expression analysis , 2006, Bioinform..

[13]  Y. Hayashi,et al.  KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. , 2006, Blood.

[14]  Aravind Subramanian,et al.  Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Dombkowski,et al.  Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. , 2006, Blood.

[16]  E. Estey,et al.  Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. , 2006, Blood.

[17]  E. Solary,et al.  Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .

[18]  D. Reinhardt,et al.  AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity , 2005, Leukemia.

[19]  J. Harbott,et al.  Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment , 2005, Leukemia.

[20]  Y. Ravindranath,et al.  GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. , 2005, Journal of the National Cancer Institute.

[21]  Todd A Alonzo,et al.  Mortality in overweight and underweight children with acute myeloid leukemia. , 2005, JAMA.

[22]  J. Downing,et al.  Gene expression profiling of pediatric acute myelogenous leukemia. , 2004, Blood.

[23]  L. Peterson,et al.  The 8;21 translocation in leukemogenesis , 2004, Oncogene.

[24]  S. Richards,et al.  Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome , 2003, Leukemia.

[25]  R. Arceci,et al.  Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia , 2003, Current oncology reports.

[26]  T. Alonzo,et al.  Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Paredes-Aguilera,et al.  Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children , 2003, American journal of hematology.

[28]  J. Taub,et al.  Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. , 2003, Blood.

[29]  M. Vignetti,et al.  Acute megakaryoblastic leukemia: experience of GIMEMA trials , 2002, Leukemia.

[30]  Yoshiaki Ito,et al.  In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. , 2002, Blood.

[31]  F. Behm,et al.  Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. , 2001, Blood.

[32]  T. L. Witt,et al.  Repression of Human Reduced Folate Carrier Gene Expression by Wild Type p53* , 2001, The Journal of Biological Chemistry.

[33]  D. Neuberg,et al.  Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. , 2000, Blood.

[34]  G. Gustafsson,et al.  Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? , 2000, Leukemia.

[35]  R. Hanada,et al.  The Treatment Outcome of Acute Megakaryocytic Leukemia in Down Syndrome , 2000 .

[36]  S. Hiebert,et al.  Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. , 2000, Gene.

[37]  M. Caligiuri,et al.  Molecular and Clinical Advances in Core Binding Factor Primary Acute Myeloid Leukemia: A Paradigm for Translational Research in Malignant Hematology , 2000, Cancer investigation.

[38]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[39]  J. Buckley,et al.  Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. , 1998, Blood.

[40]  J. Zhang,et al.  The AML1/ETO fusion protein activates transcription of BCL-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Alt,et al.  The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. , 1996, Cell.

[42]  F. Alt,et al.  The CBFβ Subunit Is Essential for CBFα2 (AML1) Function In Vivo , 1996, Cell.

[43]  R. Bronson,et al.  Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Krischer,et al.  Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood , 1996 .

[45]  M. Marín‐Padilla,et al.  Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Downing,et al.  AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis , 1996, Cell.

[47]  M. Gossen,et al.  Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.

[48]  A. Zipursky,et al.  Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. , 1994, Leukemia research.

[49]  J. Krischer,et al.  Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. , 1992, Blood.

[50]  C. Pui,et al.  Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia , 2007, Cancer.

[51]  G. Peters,et al.  Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. , 2002, Blood.

[52]  M. Eguchi,et al.  An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome , 2000, Leukemia.

[53]  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Chromosomal Abnormalities in 478 Children With Acute Myeloid Leukemia: Clinical Characteristics and Treatment Outcome in a Cooperative Pediatric Oncology Group Study—POG 8821 , 1999 .

[54]  J. Krischer,et al.  Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. , 1996, The New England journal of medicine.

[55]  J. Krischer,et al.  Acute Myeloid Leukemia ( AML ) in Down ' s Syndrome Is Highly Responsive to Chemotherapy : Experience on Pediatric Oncology Group AML Study , 2022 .